Ibere Pharmaceuticals (IBER) Financial Statements (2024 and earlier)

Company Profile

Business Address 2005 MARKET STREET, SUITE 2030
PHILADELPHIA, PA 19103
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 677 - Blank Checks (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2022
MRQ
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 458,388
Cash and cash equivalents 458,388
Prepaid expense 235,000
Total current assets: 693,388
Noncurrent Assets
Asset, held-in-trust 138,016,940
Total noncurrent assets: 138,016,940
TOTAL ASSETS: 138,710,328
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Debt 1,500,000
Other undisclosed current liabilities (1,127,556)
Total current liabilities: 372,444
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 11,166,900
Total noncurrent liabilities: 11,166,900
Total liabilities: 11,539,344
Equity
Equity, attributable to parent, including: (10,845,956)
Accumulated deficit (10,846,301)
Other undisclosed equity, attributable to parent 345
Other undisclosed equity 138,016,940
Total equity: 127,170,984
TOTAL LIABILITIES AND EQUITY: 138,710,328

Income Statement (P&L) (USD)

9/30/2022
TTM
12/31/2021
Revenues
(Net Investment Income)
 176
Gross profit: 176
Operating expenses (1,004,148)
Other undisclosed operating loss (176)
Operating loss: (1,004,148)
Nonoperating income 2,565,895
Income from continuing operations: 1,561,747
Income before gain (loss) on sale of properties:1,561,747
Net income attributable to parent: 1,561,747
Preferred stock dividends and other adjustments (13,393,944)
Net loss available to common stockholders, diluted: (11,832,197)

Comprehensive Income (USD)

9/30/2022
TTM
12/31/2021
Net income: 1,561,747
Comprehensive income, net of tax, attributable to parent: 1,561,747

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: